Medication Guide App

Daclizumab

In the US, Daclizumab (daclizumab systemic) is a member of the drug class interleukin inhibitors and is used to treat Organ Transplant - Rejection Prophylaxis and Rheumatoid Arthritis.

US matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L04AA08,L04AC01

CAS registry number (Chemical Abstracts Service)

0152923-56-3

Chemical Formula

C6394-H9888-N1696-O2012-S44

Molecular Weight

144129

Therapeutic Category

Immunosuppressant

Chemical Name

Immunoglobulin G 1 (human-mouse monoclonal clone 1H4 þ-chain anti-human interleukin 2 receptor), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer

Foreign Names

  • Daclizumabum (Latin)
  • Daclizumab (German)
  • Daclizumab (French)
  • Daclizumab (Spanish)

Generic Names

  • Daclizumab (OS: USAN, BAN, DCF)
  • Ro 24-7375 (IS)

Brand Names

International Drug Name Search

Glossary

TermDefinition
BANBritish Approved Name
DCFDénomination Commune Française
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Hide
(web3)